Huiyu Pharmaceutical's (688553.SH) subsidiary, the injection of Tilkolaning, has obtained listing approval in Ireland.

Huiyu Pharmaceuticals (688553.SH) announced that its wholly-owned subsidiary Seacross Pharma (Europe) Ltd. has recently received approval from the Irish Medicines Board for the market authorization of its product, intravenous tigecycline. Intravenous tigecycline is mainly used for the treatment of extraintestinal infections in adults and children, such as complex skin and soft tissue infections, bone and joint infections, community-acquired pneumonia, complications of urinary tract infections, infective endocarditis, persistent peritoneal dialysis-associated peritonitis, as well as bacteremia associated with the above symptoms. This product can also be used to treat Clostridium difficile-related diarrhea and colitis.